Tinea Pedis Treatment Market Trends: Climate’s Influence on Prevalence
Tinea pedis, commonly known as athlete’s foot, has emerged as a widespread foot infection, primarily prevalent in hot and tropical climates. This condition, caused by dermatophyte fungi including Trichophyton rubrum, T. interdigitale, and Epidermophyton floccosum, often accompanies other fungal infections such as tinea manuum, tinea cruris, or tinea unguium. Tinea pedis can manifest in four clinical forms, either individually or in combination: chronic hyperkeratotic, chronic intertriginous, acute ulcerative, and vesiculobullous. While males and adolescents are frequently affected, this infection can also impact females, children, and the elderly.
Read More Insights: https://www.fairfieldmarketresearch.com/report/tinea-pedis-treatment-market
The primary mode of transmission for the causative organisms is through activities like walking barefoot in public changing rooms or sharing contaminated towels. The increasing incidence of fungal and bacterial infectious diseases is a key driver of the tinea pedis treatment market. Additionally, the rising number of immunocompromised patients worldwide is further boosting demand. As the focus sharpens on research and development for more effective treatments, the market is poised for significant growth. However, companies in the global tinea pedis treatment market are challenged by regulatory requirements for treatment approvals, and the consistently growing geriatric population is also contributing to market expansion.
Aggressive Clinical Representation of Interdigital Tinea Pedis to Augment Demand for Tinea Pedis Treatment
Research estimates the prevalence of tinea pedis to range from 3% to 10% depending on climatic conditions around the world. Astonishingly, some literature suggests that approximately 70% of people globally are likely to develop athlete’s foot at some point in their lives. Interdigital tinea pedis, in particular, is more common than other forms. It is predominantly caused by T. rubrum and occurs in the spaces between the fourth and fifth toes, sometimes extending to the entire foot. This high prevalence has led to a heightened focus on the treatment of interdigital tinea pedis. Other forms include plantar tinea pedis and vesicular tinea pedis. The availability of over-the-counter (OTC) treatments, affordable drug options, and ongoing product innovations are expected to propel the tinea pedis treatment market’s growth in the coming years.
Growing Demand for Combination Therapies, Coupled with a Strong Product Pipeline, Upholds Tinea Pedis Treatment Market
Combination therapy has gained significant traction as a treatment option, combining systemic and topical treatments to achieve higher efficacy and faster results while preventing disease recurrence. For example, the combination of topical terbinafine, 10% urea ointment, and oral terbinafine has been considered the most efficient method for treating tinea pedis. Furthermore, numerous promising topical drug agents are currently in various stages of development. These drugs are expected to offer superior safety and efficacy profiles. Novan, Inc. is actively developing SB208, a nitric oxide-releasing topical drug candidate, which has shown promising results in its phase 1 clinical trial for the treatment of fungal infections of the skin and nails.
Topical Antifungals Rule Tinea Pedis Treatment Market
Topical antifungals are widely preferred and considered the safest treatment option for tinea pedis. Commonly used antifungal drugs include clotrimazole, ketoconazole, econazole, terbinafine, miconazole, itraconazole, griseofulvin, terbinafine, and sulconazole. Recurrence of the infection is common, often requiring prolonged treatment. In cases of recurrence and moisture development, oral antifungals and drying agents are employed as a second line of treatment. Commonly recommended drying agents include antifungal powders (e.g., miconazole), Burow solution (5% aluminum subacetate), gentian violet, and 20-25% aluminum chloride solution. Oral antifungals are typically reserved for medium to severe cases requiring long-term responses. However, addressing the low efficacy of the current treatment regimen remains a longstanding challenge for the expansion of the tinea pedis treatment market.
North America and Europe are Prominent Regions
The United States and European countries currently dominate the global tinea pedis treatment market. In 2018, an estimated 34 million undiagnosed cases of diabetes in the US highlighted a significant at-risk population within the country. In Europe, the growing elderly population is contributing to increased demand for tinea pedis treatment. Additionally, the emphasis on physical appearance and grooming in these regions is another factor driving demand for tinea pedis treatment.
Key Market Players Prioritize Collaborative Activities to Strengthen Market Positioning
Prominent companies in the global tinea pedis treatment market, including Alva-Amco Pharmacal Companies, Inc., Novan Inc., Aurobindo Pharma Limited, Mylan N.V, Cipla Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., ProFoot, Inc., Qilu Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Taro Pharmaceutical Industries Ltd., Sun Pharmaceuticals Limited, Bayer AG, Breckenridge Pharmaceutical, Inc., and Perrigo Company, are actively seeking collaboration opportunities to enhance their global market positioning and achieve greater market penetration.
Global Industry Analysis (2018 – 2021) – Growth Trends and Market Forecast (2022 – 2029) https://www.fairfieldmarketresearch.com/report/tinea-pedis-treatment-market
Visit Our Blogs:
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad